Phase II trial of weekly irinotecan and carboplatin for relapsed ovarian cancer: A Kansai Clinical Oncology Group study.
H. Tsubamoto
No relevant relationships to disclose
K. Inoue
No relevant relationships to disclose
R. Kawaguchi
No relevant relationships to disclose
K. Ito
No relevant relationships to disclose
S. Takeuchi
No relevant relationships to disclose
T. Shiozaki
No relevant relationships to disclose
Y. Itani
No relevant relationships to disclose
A. Arakawa
No relevant relationships to disclose
T. Tabata
No relevant relationships to disclose
S. Toyoda
No relevant relationships to disclose